FY2028 Earnings Estimate for BMY Issued By Leerink Partnrs

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at Leerink Partnrs increased their FY2028 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Tuesday, October 22nd. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will earn $6.40 per share for the year, up from their prior estimate of $6.24. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $0.77 per share.

BMY has been the subject of a number of other research reports. Barclays raised their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an "underweight" rating in a research note on Monday, October 7th. TD Cowen raised their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a "hold" rating in a research report on Monday, October 7th. UBS Group boosted their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a "neutral" rating in a report on Wednesday, October 9th. BMO Capital Markets restated a "market perform" rating and set a $48.00 price target on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $53.20.

Bristol-Myers Squibb Stock Up 1.2 %

Shares of Bristol-Myers Squibb stock opened at $52.76 on Wednesday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $56.77. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The company has a 50-day moving average of $50.53 and a 200 day moving average of $46.35. The firm has a market cap of $106.95 billion, a price-to-earnings ratio of -17.02, a PEG ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.43. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.75 earnings per share.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.55%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb's payout ratio is currently -77.42%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BMY. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth approximately $27,000. LGT Financial Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 227 shares in the last quarter. ORG Wealth Partners LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter worth $34,000. MFA Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the second quarter valued at $39,000. Finally, Beach Investment Counsel Inc. PA bought a new stake in Bristol-Myers Squibb during the second quarter valued at about $42,000. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.